Achieving High-Titer AAV Manufacturing with Proprietary Cell Line Development

Overview

In this white paper, one of our leading vector development scientists at our Milan Cell and Gene Center of Excellence addresses some common questions, challenges and best practices for developing proprietary AAV cell lines, including advantages of clonal selection, genetic engineering considerations, packaging/producer cell development, cost, access, and more.

Key Takeaways

• The power of producer cell lines for large-scale production and commercialization

• Strike the right balance between titers and potency

• The key to CDMO selection: balancing cost, access and scientific expertise 

• Strategies and challenges of developing an effective cell line

• Considerations for working with multiple serotypes and genes of interest